Third Quarter 2008 Financial Highlights
* Sales USD 87.3 million, up by 6%
* EBITDA USD 21.1 million, up by 50%
* EBITDA margin 24%, compared to 17% in Q3 2007
* Net profit USD 13.7 million, compared to USD 2.2 million in Q3
2007
* Cash EPS diluted 4.60 US cents, compared to 2.10 US cents in Q3
2007
* EPS diluted 3.24 US cents, compared to 0.56 US cents in Q3 2007
YTD 2008 Financial Highlights
* Sales USD 269.9 million, up by 8%
* EBITDA USD 63.1 million, up by 52%
* EBITDA margin 23%, compared to 17% for the same period 2007
* Net profit USD 24.3 million, compared to USD 0.9 million for the
same period 2007
* Cash EPS diluted 10.0 US cents, compared to 4.94 US cents, for
the same period 2007
* EPS diluted 5.75 US cents, compared to 0.24 US cents, for the
same period 2007
Jon Sigurdsson, President & CEO, comments:"We are quite satisfied with the results for the quarter and the
first nine months of the year. We have managed to increase the
profitability of our business handsomely, despite the fact that sales
growth has been slower than anticipated. In the past two years we
have focused on integration and to build a strong player in the field
of non-invasive orthopaedics. Today Ossur has a diverse revenue base,
well balanced between Europe and the United States and strong balance
sheets with a 43% equity ratio. We do not expect the financial
crisis in the world today to have significant impact on Ossur's
operations as Ossur operates within the health care sector. Overall,
we are confident that we have managed to build a strong Company with
a solid foundation for future growth."
Live comments form the CEO, see link here below:
www.ossur.com/ceocomments
The press release including tables, the Market Presentation Q3 2008
and the Financial Statement Q3 2008 can be downloaded from the
following links:
